leadf
logo-loader
viewAequus Pharmaceuticals Inc.
(
TSX-V:AQSOTCQB:AQSZF
)

Aequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022

There is potential to extend the current partnership beyond February 2022 and expand to include additional products beyond Vistitan and Tacrolimus IR

Aequus Pharmaceuticals Inc. -  Aequus Pharmaceuticals to maintain commercial relationship with Sandoz
Aequus is a growing specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) will maintain its current commercial relationship pertaining to the Vistitan glaucoma drug, with Sandoz into 2022.  

As a specialty pharmaceutical company, Aequus Pharmaceuticals is focused on developing, advancing and promoting differentiated products. The product line includes several medications for eye health as well as an anti-rejection drug (Tacrolimus IR) for transplant recipients. 

There is potential to extend the current partnership beyond February 2022 and could expand to include additional products beyond Vistitan and Tacrolimus IR. 

READ: Aequus Pharmaceuticals first quarter results show good progress in spite of the coronavirus pandemic

As pandemic-related lockdowns ease, the sales team at Aequus has increased outside sales and travel activity across Canada. The company plans to expand these efforts throughout the second half of the year, while continuing to engage customers digitally.

“We are delighted with the team’s flexibility to embrace digital technologies and support our customers and their patients throughout the pandemic. We anticipate many of these capabilities will continue to be leveraged to drive efficiencies once the pandemic is over,” Doug Janzen, Chairman and CEO of Aequus noted in the statement. “We will have a strong digital presence at key conferences in eye care and recently launched a new website for Vistitan.”

Contact Georgia at georgia@proactiveinvestors.com

Follow her on Twitter @MissInformd

Quick facts: Aequus Pharmaceuticals Inc.

Follow
TSX-V:AQS

Price: 0.12 CAD

Market Cap: $15.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Empower Clinics team up with SoLVBL Solutions to develop data security in...

Empower Clinics CEO Steven McAuley joined Steve Darling from Proactive to share news the company has team up with SoLVBL Solutions to create a cyber security program to detect cyber-attacks and provide data security to the diagnostic testing programs that Empower uses. McAuley telling...

36 minutes ago

2 min read